SBI Securities’s Braveheart Bio BRVE Stock Holding History

SBI Securities’s Portfolio BRVE Stock Details BRVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$202	Buy	+10	New	+$264	﹤0.01%	3416

Other funds holding BRVE

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $252M AUM 45.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SBI Securities's BRVE Position: Q3 2026 in Review

SBI Securities opened a new position in Braveheart Bio (BRVE) in Q3 2026: 10 shares worth $202. The stake represents ﹤0.01% of the portfolio and ranks #3416 among its holdings.

26 funds tracked by Wall St. Rank hold BRVE as of Q3 2026.

SBI Securities held 10 shares of Braveheart Bio worth $202 as of Q3 2026.
Braveheart Bio was a new SBI Securities position in Q3 2026.
Braveheart Bio made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3416 holding.
26 funds tracked by Wall St. Rank held Braveheart Bio as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.